NAD Nicoderm CQ ad decision being appealed to NARB by SmithKline Beecham.
This article was originally published in The Tan Sheet
Executive Summary
NAD NICODERM CQ AD DECISION APPEALED BY SMITHKLINE BEECHAM to the National Advertising Review Board, according to a NAD Case Report issued June 12. The firm disagrees with the decision of the National Advertising Division of the Council of Better Business Bureaus that its comparative advertising for Consumer Products' Nicoderm CQ nicotine replacement patches inaccurately communicates dose strengths and treatment lengths of the products being compared and should be modified. SmithKline Beecham believes NAD's solution would create confusion among consumers and asked that an NARB panel be convened to "review the truthfulness and accuracy of the advertisement at issue."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning